A case of juvenile amyopathic dermatomyositis with anti-transcription intermediary factor 1-α antibody showing negative anti-TIF1-γ ELISA results: Comment on "Case of pembrolizumab-induced dermatomyositis with anti-transcription intermediary factor 1-γ antibody"

J Dermatol. 2023 Jan;50(1):e39-e40. doi: 10.1111/1346-8138.16587. Epub 2022 Sep 29.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Comment

MeSH terms

  • Autoantibodies
  • Dermatomyositis* / chemically induced
  • Dermatomyositis* / diagnosis
  • Dermatomyositis* / drug therapy
  • Enzyme-Linked Immunosorbent Assay
  • Humans
  • Mediation Analysis

Substances

  • pembrolizumab
  • Autoantibodies

Supplementary concepts

  • Amyopathic dermatomyositis